Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Valeant Pharma (VRX) Stock: Still Not so Cheap - Barron's
May 9, 2016 7:12 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Monday following a cautious piece in Barron's published over the weekend.
The report notes that, despite shares... More
Valeant (VRX) Derm NRx Up 2.2% Week-over-Week - RBC Capital
May 6, 2016 8:44 AM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 2.2% WoW, ophth NRx were up 2.7% WoW, and Addyi NRx were down 16.2% WoW.
"For the week ending April 29th, new derm scripts (NRx) were up 2.2% vs. down 2.9% the prior week," Miehm commented. "NRx this week... More
